On the evening of February 28, Bloomage Biotechnology Co., Ltd. *** Bloomage Biotechnology, 688363SH) (hereinafter referred to as "Bloomage Biotech") released its 2023 annual performance report. According to the report, Bloomage Biotech achieved an operating income of about 60 percent during the reporting period800 million yuan, a year-on-year decrease of 437%；Net profit attributable to owners of the parent company is approximately 58.7 billion yuan, a year-on-year decrease of 395%。
At the same time, as of the end of 2023, Bloomage Biotech's total assets are about 84500 million yuan, a decrease of 262%；The owner's equity attributable to the parent company is approximately 69100 million yuan, an increase of 414%。
During the reporting period, Bloomage Biotech continued to promote its "four-wheel drive" business layout, although the company is undergoing a comprehensive upgrade and implementation of management reform, but due to the differences in the competitive environment, development stage and development model of each business, each business has different impacts in the short term.
From the perspective of business composition, Bloomage Biotech's raw material business still achieved steady growth. The medical terminal business also maintained rapid growth, while the functional skin care business experienced a phased decline. As functional skin care products accounted for the largest proportion of the company's total operating revenue, the total operating income decreased slightly compared with the same period last year.
In 2023, Bloomage Biotech's main financial data such as operating profit, total profit, net profit attributable to owners of the parent company, net profit attributable to owners of the parent company after deducting non-recurring gains and losses, and basic earnings per share will all decrease by more than 30% year-on-year. Bloomage Biotech attributed the reason to "the decline in total operating income and comprehensive gross profit margin, as well as the increase in depreciation and amortization and other expenses due to large investment in the early stage".
From November to December 2023, nearly 20 brokerages made 2023 profits for Bloomage Biotech**. The net profit of institutional analysts** is about 800 million yuan, and the net profit data released by Bloomage Biotech this time is much lower than **.
Bloomage Biotech is the most popular medical cosmetology concept stock in the past few years, with a market value of more than 150 billion yuan in 2021, and is known as "medical cosmetology".
In the face of Bloomage Biotech's latest performance report, some investors expressed surprise. "In 2023, when I saw a year-on-year decline in the functional skin care business in the second quarter, and a decline in revenue in the third quarter, I thought that the performance in the fourth quarter would be bad, but the difference in non-net profit margin could be reduced by 42% year-on-year85%, I didn't expect it at all. "This performance is almost halved, which is unacceptable to some investors.
On February 28, Bloomage Biotech reported 6077 yuan shares, with a market value of 29.3 billion yuan. In the performance report, Bloomage Biotech said that it will continue to focus on synthetic biology, adhere to the overall positioning of biotechnology companies and biomaterials companies, use scientific and technological strength to build product power, shape brand power, further increase cost reduction and efficiency increase, and promote the sustained, stable and healthy growth of the company's business.
New Yellow River Reporter: Du Lin Editor: Zhao Xiaoxin